Pharmaceuticals News
Subscribe to pharmaceutical news about research, development, manufacturing and marketing of prescription and over the counter drugs. Find the latest on FDA approvals, compliance, competition, management and distribution of pharmaceutical products as well as pharmaceutical business intelligence.
WellTouch Goes International
Marketing and services firm signs licensing deal with Mexico City-based Signufarma. - June 20, 2006 - PharmaCentra
MenScience Finds Sweet Smell of Success in Sweaty Underarms
Along with all the perks of summer (beaches, barbecues and bikinis), comes the bad—sunburn, vacation traffic and, of course, a massive increase in body odor. Fortunately, MenScience, the leader in cosmeceutical-grade skin care, has unveiled its new Advanced Deodorant just in time for the... - June 09, 2006 - MenScience Androceuticals
LGC and Gentris Corporation Announce Licensing Agreement
Gentris obtains rights from LGC to make, use and sell diagnostic products and services which include testing for the CYP2D6*4 polymorphism. - June 08, 2006 - Gentris Corporation
Cornerstone BioPharma, Inc. and Athlon Pharmaceuticals Sign Co-Promotion Agreement
Cornerstone BioPharma™, the Triangle-based specialty pharmaceutical company currently focused on the development and commercialization of niche prescription medications in the respiratory arena, today announced the company has signed a co-promotion agreement with Athlon Pharmaceuticals... - June 06, 2006 - Cornerstone BioPharma
Imminent Launches of New EPO Products and Consolidation of the Biogenerics Field
The Business Intelligence firm La Merie S.L. reported today changes in the field of erythropoiesis stimulating agents (ESA) observed in a follow-up analysis. The first launch of a new ESA in Europe is expected to be Shire’s epoetin omega in the first half of 2007 to be followed by... - June 03, 2006 - La Merie Business Intelligence
Localized Delivery of PDE-4 Inhibitors to Open the Therapeutic Window
The Localized delivery of phosphodiesterase-4 (PDE-4) inhibitors appears to be short term solution to overcome the dose-limiting side effects of severe nausea and emesis occurring after oral administration. In the long-term, subtype-selective PDE-4 inhibitors and combination regimens may help to improve the therapeutic index. - May 31, 2006 - La Merie Business Intelligence
Resveracine Ultimate Antioxidant Powerhouse, Now Offered by Advanced Nutriceuticals
Advanced Nutriceuticals now offers Resveracine, heralded as "The Ultimate Antioxidant Powerhouse." Resveracine is formulated by Dr James Chappell to provide the highest level of free radical scavenging antioxidants known in the world today. - May 23, 2006 - Health and Beauty Net
The Next Generation of Interferons Needs Improvement in Efficacy and Safety
The interferon alpha market is smaller than the interferon beta market, but is characterized by far more products and R&D projects. Conversion of the interferon alpha market to pegylated products explains why new R&D is focused on interferon alpha variants or other subtypes with improved pharmacodynamic and safety properties. - May 19, 2006 - La Merie Business Intelligence
Now available on CD: Baxa Corporation Exhibitor’s Theatre Offering, 'What’s Next with USP 797?' from ASHP Midyear Clinical Meeting
Colorado-based pharmacy products manufacturer, Baxa Corporation now has a CD available of the presentation, 'What’s Next with USP 797?' from the annual American Society of Health-System Pharmacists Midyear Clinical Meeting in Las Vegas. Eric Kastango, MBA, RPh, discussed the proposed changes to the USP 797 guidelines for sterile compounding and the impact on the hospital pharmacy practice. - May 10, 2006 - Baxa Corporation
RNA Interference (RNAi) is Coming of Age as a Therapeutic Modality
The Business Intelligence firm La Merie S.L. reported today that the RNAi therapeutic pipeline is rapidly filling and advancing towards clinical development. Four RNAi therapeutic projects are in early clinical development. At least 32 RNAi projects are in preclinical development in a variety of... - May 10, 2006 - La Merie Business Intelligence
JKZ Ventures Launches New How To Guide to Reduce Pharmacist's Dispensing Errors
Ten years of proven technique reduce or eliminate your dispensing errors. - May 04, 2006 - JKZ Ventures, Inc
Pharmaceutical Resources Group Welcomes Mary Lou Freathy, JD, as its Newest Member
Freathy Brings Experience in Pharmaceutical Compliance and Quality Assurance to the Network. - May 04, 2006 - Pharmaceutical Resources Group
Gentris Announces UGT1A1 Sub-Licensing Agreement
Gentris obtains rights from Mayo Foundation for Medical Education and Research to provide genetic testing services for mutations associated with adverse reactions to irinotecan. - April 26, 2006 - Gentris Corporation
Gentris Corporation Introduces Human Genomic DNA Reference Controls for CYP2D6 Gene
Gentris Corporation, a leading global provider of applied clinical pharmacogenomic services and diagnostic product solutions, today announced the availability of Human Genomic DNA Reference Controls for the Cytochrome P450 2D6 gene (CYP2D6). - April 13, 2006 - Gentris Corporation
Pharmaceutical Resources Group is Accepting New Members for its Free Online Network
PRG is Currently Accepting Pharmaceutical, Biotechnology, and Medical Device Professionals. - April 07, 2006 - Pharmaceutical Resources Group
Dawn has Broken for Obesity Treatment with Cannabinoid Receptor (CB1) Antagonists
Tremendous impetus to discovery of novel CB1 antagonists by first-in-class CB1 receptor antagonist rimonabant under review by FDA and EMEA - February 22, 2006 - La Merie Business Intelligence
Top 20 Biologics Now with Sales of US$ 37.7 Bln in 2005
The Top 20 blockbuster recombinant proteins and antibodies achieved record sales of US$ 37.7 bln in the year 2005 while combined sales of the 12 Top selling classes of recombinant proteins and antibodies reached the US$ 50 bln threshold. - February 15, 2006 - La Merie Business Intelligence
Emerging Diabetes Drugs in Early Development
The complexity of glucose metabolism and the number of cellular processes affected by diabetes provides ample space for new drug targets and for first-in-class molecules. Some of them have reached or are close to early clinical development in type 2 diabetes. - January 31, 2006 - La Merie Business Intelligence
Emerging Pharmaceutical Sales & Marketing Company CaraMedica Closes Series A Funding Round
Company poised for national rollout of products focused on the rapidly growing cosmetic/aesthetic surgery market. - December 21, 2005 - CaraMedica Pharmaceuticals
Gentris Announces Promotion and Strategic New Hire
Scott Clark promoted to Vice President of Research and Development; Heath Knight joins as Vice President of Business Development - December 15, 2005 - Gentris Corporation
New Life Scientific, Inc. and Telomolecular Corp Announce Strategic Alliance Agreement
New Life Scientific, Inc. (OTCBB:NWLF - News) and Telomolecular Corp, have announced a strategic alliance to develop products that treat aging and age-related disease. New Life Scientific, Inc a company engaged in developing pharmaceutical products as well as managing PharmaTrials International... - December 05, 2005 - New Life Scientific, Inc.
Gentris Joins Personalized Medicine Coalition
Educational and advocacy group to promote the advancement and understanding of personalized medicine. - December 05, 2005 - Gentris Corporation
Baxa to Sponsor Exhibitor’s Theatre: “What’s Next with USP 797?” at ASHP Midyear Clinical Meeting
Colorado-based pharmacy products manufacturer, Baxa Corporation is sponsoring a program at the annual American Society of Health-System Pharmacists Midyear Clinical Meeting in Las Vegas. The speaker will discuss the proposed changes to the USP 797 guidelines for sterile compounding and their impact on pharmacy practice. - December 02, 2005 - Baxa Corporation
Baxa to Launch ValiMed™ Medication Validation System at ASHP Midyear Meeting
Baxa Corporation announces its launch of the ValiMed System for medication safety at booth no. 2221 at the American Society of Health-System Pharmacists Midyear Meeting to be held December 4 – 8, 2005 in Las Vegas, Nev. The innovative ValiMed Technology offers validation of medication to ensure the type and strength of high-risk medications. The technology also validates narcotic returns and identifies counterfeit medications. - November 29, 2005 - Baxa Corporation
Cardiovascular safety determines the direction of PPAR agonist R&D
The two peroxisome proliferator-activated receptor (PPAR) gamma agonists pioglitazone and rosiglitazone approved for treatment of type 2 diabetes achieved combined 2004 global sales of US$ 3.96 bln shared between Takeda & Eli Lilly (52 %) and GlaxoSmithKline (48 %). - November 28, 2005 - La Merie Business Intelligence
Baxa Corporation and Carmel Pharma ab End Exclusive Distribution Agreement for PhaSeal®
Carmel Pharma elects to end Baxa distribution and establishes a US headquarters: Baxa Corporation announced today that its exclusive US distribution rights for the PhaSeal Products will end on December 31, 2005. The products’ Swedish manufacturer, Carmel Pharma ab, has elected not to continue the agreement. Over the course of the agreement, Baxa more than tripled annual PhaSeal product sales. Today, PhaSeal is used in more than 300 leading cancer treatment facilities nationwide. - November 14, 2005 - Baxa Corporation
Competition is Needed in the Follicle Stimulating Hormone (FSH) Market
Ten years after the first approval of a recombinant human FSH for treatment of infertility the US$ 0.9 bln global market of recombinant human FSH (rhFSH) in 2004 was shared between Serono (63 % for follitropin alfa) and Organon (37 % for follitropin beta). - November 14, 2005 - La Merie Business Intelligence
Licensing Opportunity Available to Pharmaceutical Companies
Med Services Europe announced that it has obtained rights to out-license a portfolio of prescription pharmaceuticals. (www.MedServicesEurope.com) - September 08, 2005 - Med Services Europe GmbH
Baxa Features Exacta-Med® And Closed System Technology For Safe Handling And Administration Of Fluid Drugs At Interphex 2005
Baxa Corporation will present its proprietary systems designed to enhance the safety and efficiency of fluid medication handling and delivery at the 26th annual Interphex Conference and Exhibition -- April 26 – 28 at the Jacob K. Javits Center in New York. Its Exacta-Med products offer added value to packaged pharmaceuticals as part of a complete drug delivery system. - April 26, 2005 - Baxa Corporation
Baxa CEO Greg Baldwin Joins Healthprolink Board of Directors
Greg Baldwin, Chairman and CEO of Baxa Corporation of Englewood, Colorado, has joined the Board of Directors for Healthprolink of Bellevue, Washington. Baxa Corporation, a privately held company, is a leader in serving hospital pharmacy systems for handling, packaging and administering liquid medications from oral to multi-ingredient IV. Baxa is a registered medical device manufacturer with the FDA and has sales in over 35 countries. - March 30, 2005 - Baxa Corporation